SIRPalpha+ PD-L1+ bone marrow macrophages aid AML growth by modulating T cell function
Birch, F.; Gonzalez-Anton, S.; Haltalli, M. L. R.; Chakravarty, P.; Bruno, F.; Georgiou, C.; Mai, C.; Todd, Y.; Payne, E.; Blum, S.; Pospori, C.; Arber, C.; Burt, R.; Tissot, F. S.; Celso, C. L.
Show abstract
Acute myeloid leukemia (AML) continues to have a poor prognosis due to its ability to relapse following initial response to chemotherapy. While immunotherapies hold the promise to revolutionize cancer treatment, AML has been particularly challenging to target. It is therefore important to better understand the relationship between AML cells and immune cells within the bone marrow (BM) microenvironment, where this disease grows. Here we focus on non-malignant BM macrophages, and using a combination of intravital microscopy, flow cytometry, transcriptomics and functional analyses we identify a subpopulation of immunomodulatory BM macrophages (IMMs) with a unique profile and function during AML progression. While the majority of macrophages are already being lost at early infiltration, IMMs are locally enriched. They are capable of efferocytosis and support AML growth through inhibition of T cells. Enrichment of IMMs in the BM of patients developing early relapse indicates that future development of interventions that target IMMs development and function may improve AML patients outcome.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 97%
- SCD inhibition eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy 96%
- A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis 96%
Similar papers in this journal
- A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy 98%
- Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia 98%
- An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML 97%
Similar papers in this journal
Similar papers in this journal
- A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML 98%
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 97%
- CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis 95%
Similar papers in this journal
- N-MYC regulates Cell Survival via eIF4G1 in inv(16) Acute Myeloid Leukemia 96%
- TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition 94%
- Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.